{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stable disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"A 95% confidence interval was intended to be estimated via binomial proportions, but was not computed due to small sample size.\n\nCriteria for Response from EBMT, IBMTR, ABMTR: Complete Response:Complete absence of monoclonal protein by immunofixation for a minimum of 6 weeks; Near Complete Response:Absence of serum paraprotein by standard serum/urine protein electrophoresis without disappearance of monoclonal spike by immunofixation; Partial Response:Sustained decrease in production rate of monoclonal serum protein to 50% or less of pretreatment value; Stable Disease: No significant change from baseline; Progression of Disease:Patients with a \\> or = 25% rise in production rate, new/increased size of lytic lesions/plasmacytomas/progressive marrow plasmacytosis; Symptomatic Deterioration:Patients with deterioration of health requiring discontinuation of treatment w/out objective evidence of disease progression.","groups":[{"description":"Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\naflibercept: Given IV","id":"OG000","title":"Treatment (Antiangiogenesis Therapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At baseline and every 4 weeks during study treatment until treatment discontinuation due to disease progression, unacceptable toxicities and/or patient withdrawal.","title":"Overall Response Rate (Complete [CR] and Partial Response [PR])","type":"PRIMARY","unitOfMeasure":"participants"}